BCL9L and invasive breast carcinoma: Consistent with our analysis, using a separate breast cancer data set (provisional TCGA; 959 cases) Elsarraj et al. reported significant levels of gene alteration for BCL9 (26%) and BCL9L (5%) in invasive breast cancers, mainly through gene amplification and partly by mRNA upregulation [21].